<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Eli Lilly & Company (LLY) — Investment Memo</title>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;600;700;900&family=DM+Sans:wght@300;400;500;600;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
:root{--bg:#0a0c10;--surface:#12151c;--surface-2:#1a1e28;--surface-3:#222836;--border:#2a3040;--accent:#e63946;--accent-glow:rgba(230,57,70,.15);--green:#06d6a0;--green-dim:rgba(6,214,160,.12);--gold:#ffd166;--blue:#118ab2;--text:#e8eaf0;--text-dim:#8892a8;--text-muted:#5a6380;--serif:'Playfair Display',Georgia,serif;--sans:'DM Sans',-apple-system,sans-serif;--mono:'JetBrains Mono',monospace}
*{margin:0;padding:0;box-sizing:border-box}html{scroll-behavior:smooth}body{background:var(--bg);color:var(--text);font-family:var(--sans);line-height:1.65;overflow-x:hidden}::selection{background:var(--accent);color:#fff}
body::before{content:'';position:fixed;inset:0;background-image:url("data:image/svg+xml,%3Csvg viewBox='0 0 256 256' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='n'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.9' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23n)' opacity='0.03'/%3E%3C/svg%3E");pointer-events:none;z-index:9999}
::-webkit-scrollbar{width:6px}::-webkit-scrollbar-track{background:var(--bg)}::-webkit-scrollbar-thumb{background:var(--border);border-radius:3px}
.scroll-progress{position:fixed;top:0;left:0;height:3px;background:linear-gradient(90deg,var(--accent),var(--gold),var(--green));z-index:10000;width:0}
#cursor-canvas{position:fixed;top:0;left:0;width:100%;height:100%;pointer-events:none;z-index:9998}
nav{position:fixed;top:0;left:0;right:0;z-index:100;background:rgba(10,12,16,.6);backdrop-filter:blur(24px);border-bottom:1px solid rgba(42,48,64,0);padding:0 48px;height:56px;display:flex;align-items:center;justify-content:space-between;transition:background .4s,border-color .4s,box-shadow .4s}
nav.scrolled{background:rgba(10,12,16,.92);border-bottom:1px solid var(--border);box-shadow:0 4px 30px rgba(0,0,0,.3)}
.nav-left{display:flex;align-items:center;gap:24px}.nav-ticker{font-family:var(--mono);font-size:13px;font-weight:500;color:var(--text);letter-spacing:1px}.nav-ticker span{color:var(--text-muted);font-weight:400}
.nav-links{display:flex;gap:4px}.nav-links a{color:var(--text-dim);text-decoration:none;font-size:12px;font-weight:500;letter-spacing:.5px;text-transform:uppercase;padding:6px 12px;border-radius:4px;transition:all .25s;position:relative}
.nav-links a::after{content:'';position:absolute;bottom:2px;left:50%;width:0;height:1px;background:var(--accent);transition:all .3s cubic-bezier(.22,1,.36,1);transform:translateX(-50%)}
.nav-links a:hover{color:var(--text)}.nav-links a:hover::after{width:60%}.nav-links a.active{color:var(--accent)}.nav-links a.active::after{width:60%}
.nav-badge{background:var(--green);color:#000;font-size:11px;font-weight:700;letter-spacing:1.5px;padding:4px 14px;border-radius:3px;text-transform:uppercase;animation:badgePulse 3s ease-in-out infinite}
@keyframes badgePulse{0%,100%{box-shadow:0 0 0 0 rgba(6,214,160,.4)}50%{box-shadow:0 0 16px 4px rgba(6,214,160,.15)}}
.hero{padding:160px 48px 100px;position:relative;overflow:hidden;min-height:100vh;display:flex;flex-direction:column;justify-content:center}
.hero-orb{position:absolute;border-radius:50%;filter:blur(80px);pointer-events:none;will-change:transform}
.hero-orb-1{top:-10%;right:-5%;width:700px;height:700px;background:radial-gradient(circle,rgba(230,57,70,.12) 0%,transparent 70%);animation:oF1 20s ease-in-out infinite}
.hero-orb-2{bottom:-15%;left:-10%;width:500px;height:500px;background:radial-gradient(circle,rgba(6,214,160,.08) 0%,transparent 70%);animation:oF2 25s ease-in-out infinite}
.hero-orb-3{top:30%;left:40%;width:300px;height:300px;background:radial-gradient(circle,rgba(17,138,178,.06) 0%,transparent 70%);animation:oF3 18s ease-in-out infinite}
@keyframes oF1{0%,100%{transform:translate(0,0) scale(1)}33%{transform:translate(-40px,30px) scale(1.05)}66%{transform:translate(20px,-20px) scale(.95)}}
@keyframes oF2{0%,100%{transform:translate(0,0) scale(1)}33%{transform:translate(30px,-40px) scale(1.08)}66%{transform:translate(-20px,20px) scale(.92)}}
@keyframes oF3{0%,100%{transform:translate(0,0) scale(1)}50%{transform:translate(-30px,30px) scale(1.1)}}
.hero-grid{position:absolute;inset:0;background-image:linear-gradient(rgba(42,48,64,.15) 1px,transparent 1px),linear-gradient(90deg,rgba(42,48,64,.15) 1px,transparent 1px);background-size:80px 80px;mask-image:radial-gradient(ellipse 60% 60% at 50% 50%,black,transparent);animation:gridPan 40s linear infinite;pointer-events:none}
@keyframes gridPan{0%{transform:translate(0,0)}100%{transform:translate(80px,80px)}}
.hero-label{font-size:11px;font-weight:600;letter-spacing:3px;text-transform:uppercase;color:var(--accent);margin-bottom:20px;display:flex;align-items:center;gap:10px;position:relative;z-index:2}
.hero-label::before{content:'';width:0;height:1px;background:var(--accent);animation:lineExpand 1s .3s cubic-bezier(.22,1,.36,1) forwards}@keyframes lineExpand{to{width:32px}}
.hero h1{font-family:var(--serif);font-size:clamp(42px,6vw,76px);font-weight:900;line-height:1.05;color:var(--text);max-width:900px;margin-bottom:20px;position:relative;z-index:2}
.hero-sub{font-size:18px;color:var(--text-dim);max-width:640px;margin-bottom:56px;font-weight:300;position:relative;z-index:2}
.reveal{opacity:0;transform:translateY(40px);transition:opacity .8s cubic-bezier(.22,1,.36,1),transform .8s cubic-bezier(.22,1,.36,1)}.reveal.visible{opacity:1;transform:translateY(0)}
.stagger-children .reveal:nth-child(1){transition-delay:0s}.stagger-children .reveal:nth-child(2){transition-delay:.08s}.stagger-children .reveal:nth-child(3){transition-delay:.16s}.stagger-children .reveal:nth-child(4){transition-delay:.24s}.stagger-children .reveal:nth-child(5){transition-delay:.32s}.stagger-children .reveal:nth-child(6){transition-delay:.4s}.stagger-children .reveal:nth-child(7){transition-delay:.48s}.stagger-children .reveal:nth-child(8){transition-delay:.56s}
.reveal-left{opacity:0;transform:translateX(-60px);transition:opacity .8s cubic-bezier(.22,1,.36,1),transform .8s cubic-bezier(.22,1,.36,1)}.reveal-left.visible{opacity:1;transform:translateX(0)}
.reveal-scale{opacity:0;transform:scale(.92);transition:opacity .7s cubic-bezier(.22,1,.36,1),transform .7s cubic-bezier(.22,1,.36,1)}.reveal-scale.visible{opacity:1;transform:scale(1)}
.hero-reveal{opacity:0;transform:translateY(30px);animation:heroFadeIn 1s cubic-bezier(.22,1,.36,1) forwards}.hero-reveal:nth-child(2){animation-delay:.15s}.hero-reveal:nth-child(3){animation-delay:.3s}.hero-reveal:nth-child(4){animation-delay:.5s}@keyframes heroFadeIn{to{opacity:1;transform:translateY(0)}}
.stats-row{display:grid;grid-template-columns:repeat(auto-fit,minmax(160px,1fr));gap:1px;background:var(--border);border:1px solid var(--border);border-radius:8px;overflow:hidden;max-width:1100px;position:relative;z-index:2}
.stat-card{background:var(--surface);padding:24px 28px;transition:background .3s;position:relative;overflow:hidden}
.stat-card::before{content:'';position:absolute;inset:0;background:linear-gradient(135deg,rgba(230,57,70,.06) 0%,transparent 60%);opacity:0;transition:opacity .4s}.stat-card:hover::before{opacity:1}
.stat-card.highlight{background:linear-gradient(135deg,var(--surface) 0%,rgba(230,57,70,.06) 100%)}
.stat-label{font-size:10px;font-weight:600;letter-spacing:2px;text-transform:uppercase;color:var(--text-muted);margin-bottom:8px}
.stat-value{font-family:var(--mono);font-size:24px;font-weight:500;color:var(--text)}.stat-value.green{color:var(--green)}.stat-value.accent{color:var(--accent)}
.stat-sub{font-size:11px;color:var(--text-muted);margin-top:4px}
.section{padding:100px 48px;max-width:1200px;margin:0 auto;position:relative}
.section-divider{width:100%;height:1px;background:linear-gradient(90deg,transparent,var(--border),transparent);max-width:1200px;margin:0 auto;position:relative;overflow:hidden}
.section-divider::after{content:'';position:absolute;top:0;left:-100%;width:60%;height:100%;background:linear-gradient(90deg,transparent,var(--accent),transparent);opacity:0;transition:opacity .5s}
.section-divider.visible::after{opacity:.5;animation:dividerSweep 1.5s ease-out forwards}@keyframes dividerSweep{to{left:140%}}
.section-header{display:flex;align-items:center;gap:16px;margin-bottom:40px}
.section-num{font-family:var(--mono);font-size:12px;color:var(--accent);letter-spacing:1px;opacity:0;transform:translateX(-20px);transition:all .6s cubic-bezier(.22,1,.36,1)}
.section-header.visible .section-num{opacity:1;transform:translateX(0)}
.section-title{font-family:var(--serif);font-size:32px;font-weight:700;color:var(--text);opacity:0;transform:translateX(-20px);transition:all .6s .1s cubic-bezier(.22,1,.36,1)}
.section-header.visible .section-title{opacity:1;transform:translateX(0)}
.thesis-box{background:linear-gradient(135deg,var(--surface) 0%,rgba(230,57,70,.04) 100%);border:1px solid var(--border);border-left:3px solid var(--accent);border-radius:0 8px 8px 0;padding:40px;margin-bottom:40px;position:relative;overflow:hidden}
.thesis-box::after{content:'';position:absolute;top:0;left:-3px;width:3px;height:0;background:var(--accent);box-shadow:0 0 12px var(--accent),0 0 24px rgba(230,57,70,.3);transition:height 1.2s cubic-bezier(.22,1,.36,1)}
.thesis-box.visible::after{height:100%}
.thesis-box h3{font-family:var(--serif);font-size:22px;font-weight:700;margin-bottom:16px}.thesis-box p{color:var(--text-dim);font-size:15px;line-height:1.8}
.thesis-points{display:grid;grid-template-columns:repeat(auto-fit,minmax(300px,1fr));gap:20px;margin-top:32px}
.thesis-point{background:var(--surface-2);border:1px solid var(--border);border-radius:8px;padding:28px;position:relative;overflow:hidden;transition:transform .4s cubic-bezier(.22,1,.36,1),border-color .4s,box-shadow .4s}
.thesis-point:hover{transform:translateY(-4px);border-color:var(--accent);box-shadow:0 12px 40px rgba(230,57,70,.1)}
.thesis-point::before{content:'';position:absolute;top:0;left:0;right:0;height:2px;background:linear-gradient(90deg,var(--accent),transparent);transform:scaleX(0);transform-origin:left;transition:transform .5s cubic-bezier(.22,1,.36,1)}
.thesis-point:hover::before{transform:scaleX(1)}
.thesis-point-num{font-family:var(--mono);font-size:48px;font-weight:700;color:var(--surface-3);position:absolute;top:12px;right:20px;line-height:1;transition:color .3s}
.thesis-point:hover .thesis-point-num{color:rgba(230,57,70,.12)}
.thesis-point h4{font-size:15px;font-weight:700;color:var(--accent);margin-bottom:10px;text-transform:uppercase;letter-spacing:.5px}
.thesis-point p{font-size:14px;color:var(--text-dim);line-height:1.7}
.overview-grid{display:grid;grid-template-columns:2fr 1fr;gap:40px}.overview-text p{color:var(--text-dim);font-size:15px;line-height:1.85;margin-bottom:20px}.overview-text strong{color:var(--text);font-weight:600}
.revenue-mix{background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:28px}
.revenue-mix h4{font-size:12px;font-weight:600;letter-spacing:2px;text-transform:uppercase;color:var(--text-muted);margin-bottom:24px}
.mix-bar{margin-bottom:16px}.mix-bar-label{display:flex;justify-content:space-between;margin-bottom:6px}.mix-bar-label span:first-child{font-size:13px;color:var(--text);font-weight:500}.mix-bar-label span:last-child{font-family:var(--mono);font-size:13px;color:var(--text-dim)}
.mix-bar-track{height:6px;background:var(--surface-3);border-radius:3px;overflow:hidden}.mix-bar-fill{height:100%;border-radius:3px;width:0 !important;transition:width 1.2s cubic-bezier(.22,1,.36,1)}
.fill-cardio{background:linear-gradient(90deg,var(--accent),#ff6b7a)}.fill-onco{background:linear-gradient(90deg,var(--blue),#4cc9f0)}.fill-immuno{background:linear-gradient(90deg,var(--gold),#ffe066)}.fill-neuro{background:linear-gradient(90deg,var(--green),#40e0a0)}.fill-other{background:linear-gradient(90deg,var(--text-muted),#7a82a0)}
.industry-stats{display:grid;grid-template-columns:repeat(3,1fr);gap:20px;margin-bottom:40px}
.ind-stat{background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:28px;text-align:center;transition:transform .3s,border-color .3s,box-shadow .3s}
.ind-stat:hover{transform:translateY(-3px);border-color:rgba(230,57,70,.3);box-shadow:0 8px 30px rgba(0,0,0,.3)}
.ind-stat-val{font-family:var(--serif);font-size:36px;font-weight:700;color:var(--text);margin-bottom:4px}.ind-stat-label{font-size:12px;color:var(--text-muted);letter-spacing:.5px}
.market-share-visual{background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:32px}
.share-title{font-size:12px;font-weight:600;letter-spacing:2px;text-transform:uppercase;color:var(--text-muted);margin-bottom:24px}
.share-bar-row{display:flex;align-items:center;margin-bottom:12px;gap:16px}.share-bar-label{font-size:13px;font-weight:600;color:var(--text);width:120px;flex-shrink:0}
.share-bar-outer{flex:1;height:28px;background:var(--surface-3);border-radius:4px;overflow:hidden}
.share-bar-inner{height:100%;border-radius:4px;display:flex;align-items:center;justify-content:flex-end;padding-right:12px;font-family:var(--mono);font-size:12px;font-weight:500;color:#fff;width:0;transition:width 1.5s cubic-bezier(.22,1,.36,1)}
.share-lly{background:linear-gradient(90deg,var(--accent),#ff6b7a)}.share-nvo{background:linear-gradient(90deg,var(--blue),#4cc9f0)}.share-other{background:var(--text-muted)}
.catalyst-timeline{position:relative;padding-left:40px}.catalyst-timeline::before{content:'';position:absolute;left:15px;top:0;bottom:0;width:1px;background:var(--border)}
.catalyst-timeline::after{content:'';position:absolute;left:15px;top:0;width:1px;background:linear-gradient(180deg,var(--accent),var(--green));height:0;transition:height 2s cubic-bezier(.22,1,.36,1)}
.catalyst-timeline.line-animated::after{height:100%}
.catalyst-item{position:relative;margin-bottom:36px;background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:28px 32px;transition:border-color .3s,transform .3s,box-shadow .3s}
.catalyst-item:hover{border-color:var(--accent);transform:translateX(6px);box-shadow:-6px 0 20px rgba(230,57,70,.08)}
.catalyst-item::before{content:'';position:absolute;left:-33px;top:32px;width:10px;height:10px;background:var(--accent);border-radius:50%;border:2px solid var(--bg);box-shadow:0 0 0 0 rgba(230,57,70,.4);transition:box-shadow .3s}
.catalyst-item:hover::before{box-shadow:0 0 12px 4px rgba(230,57,70,.2)}
.catalyst-date{font-family:var(--mono);font-size:11px;font-weight:500;color:var(--accent);letter-spacing:1px;text-transform:uppercase;margin-bottom:8px}
.catalyst-item h4{font-size:17px;font-weight:700;color:var(--text);margin-bottom:8px}.catalyst-item p{font-size:14px;color:var(--text-dim);line-height:1.7}
.catalyst-tag{display:inline-block;background:var(--green-dim);color:var(--green);font-size:10px;font-weight:700;letter-spacing:1px;text-transform:uppercase;padding:3px 10px;border-radius:3px;margin-top:10px}
.catalyst-tag.high{background:var(--accent-glow);color:var(--accent)}
.fin-table-wrap{overflow-x:auto;margin-bottom:40px}.fin-table{width:100%;border-collapse:collapse;font-size:14px}
.fin-table thead th{font-size:10px;font-weight:600;letter-spacing:2px;text-transform:uppercase;color:var(--text-muted);text-align:right;padding:12px 16px;border-bottom:1px solid var(--border)}.fin-table thead th:first-child{text-align:left}
.fin-table tbody td{padding:14px 16px;text-align:right;font-family:var(--mono);font-size:13px;color:var(--text-dim);border-bottom:1px solid rgba(42,48,64,.4);transition:background .2s}.fin-table tbody td:first-child{text-align:left;font-family:var(--sans);font-weight:500;color:var(--text)}
.fin-table tbody tr:hover td{background:rgba(230,57,70,.03)}.fin-table .highlight-row td{color:var(--text);font-weight:500}.fin-table .growth-positive{color:var(--green)}
.product-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:16px;margin-bottom:40px}
.product-card{background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:24px;transition:transform .3s cubic-bezier(.22,1,.36,1),border-color .3s,box-shadow .3s;position:relative;overflow:hidden}
.product-card:hover{border-color:var(--accent);transform:translateY(-4px);box-shadow:0 8px 30px rgba(0,0,0,.3)}
.product-card::after{content:'';position:absolute;bottom:0;left:0;right:0;height:2px;background:linear-gradient(90deg,var(--accent),var(--green));transform:scaleX(0);transition:transform .4s cubic-bezier(.22,1,.36,1)}.product-card:hover::after{transform:scaleX(1)}
.product-name{font-size:15px;font-weight:700;color:var(--text);margin-bottom:4px}.product-area{font-size:11px;color:var(--text-muted);text-transform:uppercase;letter-spacing:1px;margin-bottom:16px}
.product-rev{font-family:var(--mono);font-size:22px;font-weight:500;color:var(--text);margin-bottom:4px}.product-growth{font-family:var(--mono);font-size:13px;color:var(--green)}
.target-banner{background:var(--surface);border:1px solid var(--border);border-radius:12px;padding:56px;text-align:center;margin-bottom:40px;position:relative;overflow:hidden}
.target-banner::before{content:'';position:absolute;inset:-2px;border-radius:14px;padding:2px;background:conic-gradient(from 0deg,var(--accent),var(--gold),var(--green),var(--blue),var(--accent));-webkit-mask:linear-gradient(#fff 0 0) content-box,linear-gradient(#fff 0 0);mask:linear-gradient(#fff 0 0) content-box,linear-gradient(#fff 0 0);-webkit-mask-composite:xor;mask-composite:exclude;animation:borderRotate 6s linear infinite;opacity:.4}
@keyframes borderRotate{to{filter:hue-rotate(360deg)}}
.target-banner .label{font-size:11px;font-weight:600;letter-spacing:3px;text-transform:uppercase;color:var(--text-muted);margin-bottom:12px}
.target-banner .price{font-family:var(--serif);font-size:72px;font-weight:900;color:var(--text);margin-bottom:8px}
.target-banner .upside{font-family:var(--mono);font-size:22px;color:var(--green);font-weight:500}.target-banner .method{font-size:13px;color:var(--text-muted);margin-top:12px}
.val-grid{display:grid;grid-template-columns:1fr 1fr;gap:24px;margin-bottom:40px}
.val-card{background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:32px}
.val-card h4{font-size:12px;font-weight:600;letter-spacing:2px;text-transform:uppercase;color:var(--text-muted);margin-bottom:24px}
.peer-row{display:grid;grid-template-columns:1.5fr 1fr 1fr 1fr;padding:10px 0;font-size:13px;border-bottom:1px solid rgba(42,48,64,.4);transition:background .2s}
.peer-row:not(.header):not(.active):hover{background:rgba(255,255,255,.02)}
.peer-row.header{font-size:10px;font-weight:600;letter-spacing:1.5px;text-transform:uppercase;color:var(--text-muted);border-bottom:1px solid var(--border);padding-bottom:12px;margin-bottom:4px}
.peer-row .name{font-weight:600;color:var(--text)}.peer-row .val{font-family:var(--mono);color:var(--text-dim);text-align:right}
.peer-row.active{background:var(--accent-glow);margin:0 -12px;padding:10px 12px;border-radius:4px;animation:activeGlow 3s ease-in-out infinite}
@keyframes activeGlow{0%,100%{box-shadow:0 0 0 0 rgba(230,57,70,0)}50%{box-shadow:0 0 12px 0 rgba(230,57,70,.08)}}
.peer-row.active .name{color:var(--accent)}.peer-row.active .val{color:var(--text)}
.dcf-grid{display:grid;grid-template-columns:auto repeat(3,1fr);gap:0;font-size:13px}
.dcf-cell{padding:10px 16px;text-align:center;font-family:var(--mono);color:var(--text-dim);border-bottom:1px solid rgba(42,48,64,.3)}
.dcf-cell.header{font-size:10px;font-weight:600;letter-spacing:1.5px;text-transform:uppercase;color:var(--text-muted);font-family:var(--sans)}
.dcf-cell.row-label{text-align:left;font-weight:500;color:var(--text)}
.dcf-cell.target{background:var(--accent-glow);color:var(--accent);font-weight:600;border-radius:4px;animation:targetPulse 3s ease-in-out infinite}
@keyframes targetPulse{0%,100%{box-shadow:inset 0 0 0 0 rgba(230,57,70,0)}50%{box-shadow:inset 0 0 12px 0 rgba(230,57,70,.1)}}
.risk-item{background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:24px 28px;margin-bottom:12px;display:grid;grid-template-columns:1fr auto;gap:20px;align-items:start;transition:border-color .3s,transform .3s}
.risk-item:hover{border-color:rgba(255,209,102,.3);transform:translateX(3px)}
.risk-title{font-size:15px;font-weight:700;color:var(--text);margin-bottom:6px}.risk-desc{font-size:13px;color:var(--text-dim);line-height:1.7}
.risk-level{font-family:var(--mono);font-size:10px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;padding:4px 12px;border-radius:3px;white-space:nowrap}
.risk-level.low{background:var(--green-dim);color:var(--green)}.risk-level.med{background:rgba(255,209,102,.12);color:var(--gold)}
footer{border-top:1px solid var(--border);padding:32px 48px;text-align:center}footer p{font-size:11px;color:var(--text-muted);line-height:1.8;max-width:900px;margin:0 auto}
@media(max-width:768px){nav{padding:0 20px}.nav-links{display:none}.hero{padding:120px 20px 60px;min-height:auto}.section{padding:60px 20px}.stats-row{grid-template-columns:repeat(2,1fr)}.overview-grid{grid-template-columns:1fr}.industry-stats{grid-template-columns:1fr}.val-grid{grid-template-columns:1fr}.risk-item{grid-template-columns:1fr}footer{padding:32px 20px}#cursor-canvas{display:none}}
.dl-card{display:flex;align-items:center;gap:20px;background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:28px 32px;text-decoration:none;color:var(--text);transition:transform .4s cubic-bezier(.22,1,.36,1),border-color .4s,box-shadow .4s;position:relative;overflow:hidden;cursor:pointer}
.dl-card:hover{transform:translateY(-4px);border-color:var(--accent);box-shadow:0 12px 40px rgba(230,57,70,.1)}
.dl-card::before{content:'';position:absolute;top:0;left:0;right:0;height:2px;background:linear-gradient(90deg,var(--accent),var(--green));transform:scaleX(0);transform-origin:left;transition:transform .5s cubic-bezier(.22,1,.36,1)}.dl-card:hover::before{transform:scaleX(1)}
.dl-icon{flex-shrink:0;width:48px;height:48px;display:flex;align-items:center;justify-content:center}
.dl-info{flex:1}.dl-title{font-size:17px;font-weight:700;margin-bottom:6px}.dl-desc{font-size:13px;color:var(--text-dim);line-height:1.6;margin-bottom:8px}
.dl-meta{font-family:var(--mono);font-size:11px;color:var(--text-muted);letter-spacing:.5px}
.dl-arrow{font-size:24px;color:var(--text-muted);transition:transform .3s,color .3s}.dl-card:hover .dl-arrow{transform:translateX(4px);color:var(--accent)}
@media(max-width:768px){.dl-card{flex-direction:column;text-align:center}.dl-arrow{display:none}}
</style>
</head>
<body>
<div class="scroll-progress" id="scrollProgress"></div>
<canvas id="cursor-canvas"></canvas>
<nav id="mainNav"><div class="nav-left"><div class="nav-ticker">LLY <span>NYSE · $1,037</span></div><div class="nav-links" id="navLinks"><a href="#thesis" data-section="thesis">Thesis</a><a href="#company" data-section="company">Company</a><a href="#industry" data-section="industry">Industry</a><a href="#catalysts" data-section="catalysts">Catalysts</a><a href="#financials" data-section="financials">Financials</a><a href="#valuation" data-section="valuation">Valuation</a><a href="#risks" data-section="risks">Risks</a></div></div><div class="nav-badge">BUY</div></nav>

<section class="hero"><div class="hero-orb hero-orb-1"></div><div class="hero-orb hero-orb-2"></div><div class="hero-orb hero-orb-3"></div><div class="hero-grid"></div>
<div class="hero-label hero-reveal">Investment Memo · February 2026</div>
<h1 class="hero-reveal">Eli Lilly &amp; Company</h1>
<p class="hero-sub hero-reveal">Three mispriced catalysts in 3–12 months. The market hasn't fully discounted the compounder exit, Medicare expansion, or oral GLP-1 approval.</p>
<div class="stats-row hero-reveal stagger-children">
<div class="stat-card highlight reveal"><div class="stat-label">Price Target</div><div class="stat-value accent" data-count="1509" data-prefix="$">$0</div><div class="stat-sub">+45% upside</div></div>
<div class="stat-card reveal"><div class="stat-label">Market Cap</div><div class="stat-value">$929B</div></div>
<div class="stat-card reveal"><div class="stat-label">FY26E Revenue</div><div class="stat-value">$81B</div><div class="stat-sub">+24% YoY</div></div>
<div class="stat-card reveal"><div class="stat-label">FY26E EPS</div><div class="stat-value">$33.28</div><div class="stat-sub">+41% growth</div></div>
<div class="stat-card reveal"><div class="stat-label">Fwd P/E</div><div class="stat-value">31.2x</div></div>
<div class="stat-card reveal"><div class="stat-label">PEG Ratio</div><div class="stat-value green">0.76x</div><div class="stat-sub">vs. 2.07x peers</div></div>
<div class="stat-card reveal"><div class="stat-label">Beta</div><div class="stat-value">0.35</div></div>
<div class="stat-card reveal"><div class="stat-label">52W Range</div><div class="stat-value" style="font-size:18px">$624–$1,134</div></div>
</div></section>

<div class="section-divider"></div>
<section class="section" id="thesis"><div class="section-header"><span class="section-num">01</span><h2 class="section-title">Investment Thesis</h2></div>
<div class="thesis-box reveal"><h3>Short-Term Mispricing (3–12 Months)</h3><p>Lilly is mispriced on three catalysts the market has not fully discounted. The FDA ended the tirzepatide shortage in late 2025, mandating compounder exit — we estimate $3–5B in annual demand recapture flowing back to Lilly as 1–2M patients switch to branded products. The April 1 Medicare deal creates a $50/month copay, opening access to ~65M beneficiaries. And the April 10 orforglipron FDA decision unlocks the ~40% of obesity patients who refuse injectables — a $10B+ TAM expansion. Lilly trades at peer-median P/E (31x) despite 41% EPS growth vs. 7% for peers. The manufacturing moat ($27B+ invested) cannot be replicated in our time horizon.</p></div>
<div class="thesis-points stagger-children">
<div class="thesis-point reveal"><div class="thesis-point-num">1</div><h4>Compounder Exit</h4><p>FDA declared tirzepatide shortage resolved — mandatory compounder wind-down forces 1–2M patients to branded products. $3–5B annual demand recapture, the most immediate catalyst.</p></div>
<div class="thesis-point reveal"><div class="thesis-point-num">2</div><h4>Medicare $50 Copay</h4><p>April 1, 2026: Zepbound access at $50/month (down from $1,000+). Opens the largest US payer (~65M beneficiaries) to obesity treatment for the first time.</p></div>
<div class="thesis-point reveal"><div class="thesis-point-num">3</div><h4>Orforglipron Approval</h4><p>April 10, 2026: FDA rules on first oral GLP-1 for obesity. Addresses ~40% of patients who refuse needles. Phase 3 showed 7–10% weight loss. TAM expansion: $10B+.</p></div>
</div></section>

<div class="section-divider"></div>
<section class="section" id="company"><div class="section-header"><span class="section-num">02</span><h2 class="section-title">Company Overview</h2></div>
<div class="overview-grid"><div class="overview-text reveal">
<p>Eli Lilly is a <strong>$929 billion</strong> global pharmaceutical company headquartered in Indianapolis, Indiana, celebrating its 150th anniversary in 2026. The company operates as a single business segment focused on discovering, developing, manufacturing, and commercializing innovative medicines across four core therapeutic areas.</p>
<p>Unlike diversified peers such as Johnson &amp; Johnson or Pfizer, Lilly has strategically concentrated on <strong>high-growth biologics and small molecules</strong> while avoiding commodity generics. The transformation accelerated with Mounjaro (tirzepatide) approval in 2022 for type 2 diabetes, followed by Zepbound approval for obesity in 2023. These GLP-1/GIP dual agonists now represent <strong>56% of total revenue ($36.5B combined in FY25)</strong> and continue growing at >100% annually.</p>
<p>Lilly employs approximately 47,000 people globally and maintains industry-leading R&amp;D investment at <strong>~20% of revenue ($13.3B in FY25)</strong>. The pipeline includes 15 programs in Phase 3, with orforglipron (first oral GLP-1) and retatrutide (triple agonist, 24%+ weight loss) as the most significant near-term opportunities. The company has committed <strong>$27B+</strong> to manufacturing capacity expansion.</p>
</div><div class="revenue-mix reveal-scale" id="revenueMix"><h4>FY25 Revenue Mix</h4>
<div class="mix-bar"><div class="mix-bar-label"><span>Cardiometabolic</span><span>56%</span></div><div class="mix-bar-track"><div class="mix-bar-fill fill-cardio" data-width="56%"></div></div></div>
<div class="mix-bar"><div class="mix-bar-label"><span>Oncology</span><span>10%</span></div><div class="mix-bar-track"><div class="mix-bar-fill fill-onco" data-width="10%"></div></div></div>
<div class="mix-bar"><div class="mix-bar-label"><span>Immunology</span><span>6%</span></div><div class="mix-bar-track"><div class="mix-bar-fill fill-immuno" data-width="6%"></div></div></div>
<div class="mix-bar"><div class="mix-bar-label"><span>Neuroscience</span><span>2%</span></div><div class="mix-bar-track"><div class="mix-bar-fill fill-neuro" data-width="2%"></div></div></div>
<div class="mix-bar"><div class="mix-bar-label"><span>Other</span><span>26%</span></div><div class="mix-bar-track"><div class="mix-bar-fill fill-other" data-width="26%"></div></div></div>
</div></div></section>

<div class="section-divider"></div>
<section class="section" id="industry"><div class="section-header"><span class="section-num">03</span><h2 class="section-title">Industry Overview</h2></div>
<div class="industry-stats stagger-children">
<div class="ind-stat reveal"><div class="ind-stat-val">$130B+</div><div class="ind-stat-label">GLP-1 Market by 2030</div></div>
<div class="ind-stat reveal"><div class="ind-stat-val">21%</div><div class="ind-stat-label">CAGR (2025–2030)</div></div>
<div class="ind-stat reveal"><div class="ind-stat-val">42%</div><div class="ind-stat-label">US Adults Classified Obese</div></div>
</div>
<div class="market-share-visual reveal-scale" id="marketShare"><div class="share-title">US Incretin Market Share (TRx) — Q3 2025</div>
<div class="share-bar-row"><div class="share-bar-label">Eli Lilly</div><div class="share-bar-outer"><div class="share-bar-inner share-lly" data-width="57.9%">57.9%</div></div></div>
<div class="share-bar-row"><div class="share-bar-label">Novo Nordisk</div><div class="share-bar-outer"><div class="share-bar-inner share-nvo" data-width="41.7%">41.7%</div></div></div>
<div class="share-bar-row"><div class="share-bar-label">Other</div><div class="share-bar-outer"><div class="share-bar-inner share-other" data-width="0.4%"></div></div></div>
<p style="font-size:13px;color:var(--text-dim);margin-top:16px"><strong style="color:var(--green)">New Rx share (NBRx): 65.1% Lilly</strong> — indicating accelerating gains as new patients overwhelmingly choose Mounjaro/Zepbound. Barriers to entry are formidable: manufacturing GLP-1 biologics at scale requires $10B+ and 5+ years.</p>
</div></section>

<div class="section-divider"></div>
<section class="section" id="catalysts"><div class="section-header"><span class="section-num">04</span><h2 class="section-title">Near-Term Catalyst Path</h2></div>
<div class="catalyst-timeline stagger-children" id="catalystTimeline">
<div class="catalyst-item reveal-left"><div class="catalyst-date">Now → Q1 2026</div><h4>FDA Compounder Wind-Down</h4><p>FDA declared tirzepatide shortage resolved in late 2025, triggering mandatory compounder exit. We estimate 1–2M patients will transition to branded products, representing $3–5B in annual demand recapture.</p><span class="catalyst-tag high">Most Immediate</span></div>
<div class="catalyst-item reveal-left"><div class="catalyst-date">April 1, 2026</div><h4>Medicare $50 Copay Begins</h4><p>Medicare beneficiaries gain Zepbound access at $50/month — down from $1,000+ previously. Opens largest US payer (~65M beneficiaries) to obesity treatment.</p><span class="catalyst-tag">TAM Expansion</span></div>
<div class="catalyst-item reveal-left"><div class="catalyst-date">April 10, 2026</div><h4>Orforglipron FDA Decision</h4><p>FDA rules on once-daily oral GLP-1 for obesity. First oral alternative to injectables, addressing ~40% of patients who refuse needles. Phase 3 showed 7–10% weight loss. TAM expansion: $10B+.</p><span class="catalyst-tag">Pipeline Catalyst</span></div>
<div class="catalyst-item reveal-left"><div class="catalyst-date">H1 2026</div><h4>SURPASS-CVOT Data</h4><p>Cardiovascular outcomes trial for tirzepatide. Positive data supports label expansion for CV risk reduction — key differentiator vs. competition and payer coverage driver.</p><span class="catalyst-tag">Label Expansion</span></div>
<div class="catalyst-item reveal-left"><div class="catalyst-date">H1 2026</div><h4>Ventyx Acquisition Closes</h4><p>$1.2B acquisition brings NLRP3 inhibitor pipeline for inflammation-driven diseases. Strengthens oral small molecule capabilities beyond incretins.</p><span class="catalyst-tag">M&A</span></div>
<div class="catalyst-item reveal-left"><div class="catalyst-date">2026–2027</div><h4>Retatrutide Phase 3</h4><p>Next-gen triple agonist (GLP-1/GIP/glucagon) with 24%+ weight loss in Phase 2 — potentially the most efficacious obesity drug ever. TRIUMPH program reading out 2026–2027.</p><span class="catalyst-tag">Next-Gen Pipeline</span></div>
</div></section>

<div class="section-divider"></div>
<section class="section" id="financials"><div class="section-header"><span class="section-num">05</span><h2 class="section-title">Financial Projections</h2></div>
<div class="fin-table-wrap reveal"><table class="fin-table"><thead><tr><th>Metric</th><th>FY24A</th><th>FY25A</th><th>FY26E</th><th>FY27E</th></tr></thead>
<tbody>
<tr><td>Revenue ($B)</td><td>$45.0</td><td>$65.2</td><td>$81.0</td><td>$87.1</td></tr>
<tr><td>YoY Growth</td><td class="growth-positive">+32%</td><td class="growth-positive">+45%</td><td class="growth-positive">+24%</td><td class="growth-positive">+8%</td></tr>
<tr><td>Gross Margin</td><td>81.3%</td><td>83.0%</td><td>82.5%</td><td>82.5%</td></tr>
<tr class="highlight-row"><td>EPS (Non-GAAP)</td><td>$13.00</td><td>$23.80</td><td>$33.28</td><td>$40.79</td></tr>
<tr><td>EPS Growth</td><td class="growth-positive">+106%</td><td class="growth-positive">+84%</td><td class="growth-positive">+41%</td><td class="growth-positive">+22%</td></tr>
</tbody></table></div>
<p class="reveal" style="font-size:14px;color:var(--text-dim);margin-bottom:40px;line-height:1.8">Management guided FY26 revenue of <strong style="color:var(--text)">$80–83B</strong> and non-GAAP EPS of <strong style="color:var(--text)">$33.50–35.00</strong>. We model $81B revenue (midpoint) and $33.28 EPS. Key drivers include Mounjaro/Zepbound volume trajectory (+115% YoY in Q4), international expansion (Mounjaro OUS +267% in Q4), easing manufacturing constraints, and Medicare access expansion (April 1) not yet in run-rate.</p>
<div class="section-header reveal" style="margin-top:48px"><span class="section-num">05.1</span><h2 class="section-title" style="font-size:24px">Key Product Performance — Q4 2025</h2></div>
<div class="product-grid stagger-children">
<div class="product-card reveal"><div class="product-name">Mounjaro</div><div class="product-area">Type 2 Diabetes</div><div class="product-rev">$7.4B</div><div class="product-growth">+110% YoY · FY25: $23.0B</div></div>
<div class="product-card reveal"><div class="product-name">Zepbound</div><div class="product-area">Obesity</div><div class="product-rev">$4.3B</div><div class="product-growth">+123% YoY · FY25: $13.5B</div></div>
<div class="product-card reveal"><div class="product-name">Verzenio</div><div class="product-area">Oncology</div><div class="product-rev">$1.6B</div><div class="product-growth">+3% YoY · FY25: $5.7B</div></div>
<div class="product-card reveal"><div class="product-name">Jardiance</div><div class="product-area">Diabetes (Collab)</div><div class="product-rev">$1.0B</div><div class="product-growth">+40% YoY · FY25: $3.6B</div></div>
<div class="product-card reveal"><div class="product-name">New Launches</div><div class="product-area">Kisunla · Jaypirca · Ebglyss · Omvoh</div><div class="product-rev">$0.4B</div><div class="product-growth">+78% YoY · FY25: $1.2B</div></div>
</div></section>

<div class="section-divider"></div>
<section class="section" id="valuation"><div class="section-header"><span class="section-num">06</span><h2 class="section-title">Valuation</h2></div>
<div class="target-banner reveal-scale"><div class="label">12-Month Price Target</div><div class="price" data-count="1509" data-prefix="$">$0</div><div class="upside">+45% Upside from $1,037</div><div class="method">DCF (8% WACC, 5% terminal growth) cross-validated against peer multiples</div></div>
<div class="val-grid">
<div class="val-card reveal"><h4>Peer Comparison</h4>
<div class="peer-row header"><span>Company</span><span class="val">Fwd P/E</span><span class="val">EPS Gr.</span><span class="val">PEG</span></div>
<div class="peer-row active"><span class="name">Eli Lilly</span><span class="val">31.2x</span><span class="val">+41%</span><span class="val">0.76x</span></div>
<div class="peer-row"><span class="name">Novo Nordisk</span><span class="val">16.0x</span><span class="val">+25%</span><span class="val">0.64x</span></div>
<div class="peer-row"><span class="name">Johnson &amp; Johnson</span><span class="val">15x</span><span class="val">+5%</span><span class="val">3.00x</span></div>
<div class="peer-row"><span class="name">Merck</span><span class="val">14x</span><span class="val">+6%</span><span class="val">2.33x</span></div>
<div class="peer-row"><span class="name">AbbVie</span><span class="val">14x</span><span class="val">+8%</span><span class="val">1.75x</span></div>
<div class="peer-row"><span class="name">Amgen</span><span class="val">13x</span><span class="val">+6%</span><span class="val">2.17x</span></div>
<div class="peer-row" style="border-top:1px solid var(--border);margin-top:8px;padding-top:12px"><span class="name" style="color:var(--text-muted)">Peer Median</span><span class="val">14.5x</span><span class="val">+7%</span><span class="val">2.07x</span></div>
</div>
<div class="val-card reveal"><h4>DCF Sensitivity — Implied Share Price</h4>
<div class="dcf-grid">
<div class="dcf-cell header"></div><div class="dcf-cell header">4% TG</div><div class="dcf-cell header">5% TG</div><div class="dcf-cell header">6% TG</div>
<div class="dcf-cell row-label">7% WACC</div><div class="dcf-cell">$1,623</div><div class="dcf-cell">$1,883</div><div class="dcf-cell">$2,247</div>
<div class="dcf-cell row-label">8% WACC</div><div class="dcf-cell">$1,326</div><div class="dcf-cell target">$1,509</div><div class="dcf-cell">$1,761</div>
<div class="dcf-cell row-label">9% WACC</div><div class="dcf-cell">$1,116</div><div class="dcf-cell">$1,248</div><div class="dcf-cell">$1,425</div>
</div>
<p style="font-size:12px;color:var(--text-muted);margin-top:20px;text-align:center">Bear (9%/4%): $1,116 (+8%) · Bull (7%/6%): $2,247 (+117%)</p>
<p style="font-size:12px;color:var(--text-muted);margin-top:8px;text-align:center">CFRA target: $1,211 (29.7x FY27E EPS) — 17% upside</p>
</div></div></section>

<div class="section-divider"></div>
<section class="section" id="risks"><div class="section-header"><span class="section-num">07</span><h2 class="section-title">Key Risks &amp; Mitigants</h2></div>
<div class="stagger-children">
<div class="risk-item reveal"><div><div class="risk-title">1. IRA Pricing on Jardiance (Jan 2026)</div><div class="risk-desc">66% discount effective now. Impact: ~$900M (1.4% FY26 rev). <strong style="color:var(--text)">Mitigant:</strong> Already in guidance; flagship incretins exempt from IRA price negotiation until 2030+.</div></div><span class="risk-level med">Medium</span></div>
<div class="risk-item reveal"><div><div class="risk-title">2. Orforglipron Approval Delay/Rejection</div><div class="risk-desc">FDA decision April 10. <strong style="color:var(--text)">Mitigant:</strong> All 4 Phase 3 trials met primary endpoints; potential delay would be procedural. Core thesis intact without orforglipron.</div></div><span class="risk-level low">Low</span></div>
<div class="risk-item reveal"><div><div class="risk-title">3. Novo Nordisk Competition</div><div class="risk-desc">Novo has oral semaglutide and CagriSema in trials. <strong style="color:var(--text)">Mitigant:</strong> LLY gaining share (NBRx 65.1%); orforglipron beat oral sema head-to-head; retatrutide 24%+ weight loss.</div></div><span class="risk-level med">Medium</span></div>
<div class="risk-item reveal"><div><div class="risk-title">4. Product Concentration (56% Incretins)</div><div class="risk-desc">Safety signal or supply disruption risk. <strong style="color:var(--text)">Mitigant:</strong> $27B manufacturing investment; Kisunla/Jaypirca diversifying pipeline; no safety signals in 3+ years of commercial use.</div></div><span class="risk-level med">Medium</span></div>
<div class="risk-item reveal"><div><div class="risk-title">5. Multiple Compression</div><div class="risk-desc">31x P/E vulnerable in risk-off environment. <strong style="color:var(--text)">Mitigant:</strong> Low beta (0.35); consistent earnings beats; dividend floor (0.7%).</div></div><span class="risk-level low">Low</span></div>
</div>
<div class="reveal" style="background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:24px 28px;margin-top:24px"><p style="font-size:14px;color:var(--text-dim);line-height:1.7"><strong style="color:var(--text)">Overall Risk: MEDIUM.</strong> Primary risks (pricing, competition) are known and priced in. Asymmetric upside from catalyst execution (compounder exit $3–5B, Medicare access, orforglipron $10B+ TAM) outweighs headwinds. <strong style="color:var(--green)">Position size: 3–5% of portfolio.</strong></p></div>
</section>



<div class="section-divider"></div>

<section class="section" id="resources" style="padding:60px 48px;text-align:center">
<a href="https://github.com/nvhung010606/elilillywebsite" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:12px;background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:20px 36px;text-decoration:none;color:var(--text);transition:transform .3s,border-color .3s,box-shadow .3s">
<svg width="24" height="24" viewBox="0 0 24 24" fill="var(--text)"><path d="M12 0C5.37 0 0 5.37 0 12c0 5.31 3.435 9.795 8.205 11.385.6.105.825-.255.825-.57 0-.285-.015-1.23-.015-2.235-3.015.555-3.795-.735-4.035-1.41-.135-.345-.72-1.41-1.23-1.695-.42-.225-1.02-.78-.015-.795.945-.015 1.62.87 1.845 1.23 1.08 1.815 2.805 1.305 3.495.99.105-.78.42-1.305.765-1.605-2.67-.3-5.46-1.335-5.46-5.925 0-1.305.465-2.385 1.23-3.225-.12-.3-.54-1.53.12-3.18 0 0 1.005-.315 3.3 1.23.96-.27 1.98-.405 3-.405s2.04.135 3 .405c2.295-1.56 3.3-1.23 3.3-1.23.66 1.65.24 2.88.12 3.18.765.84 1.23 1.905 1.23 3.225 0 4.605-2.805 5.625-5.475 5.925.435.375.81 1.095.81 2.22 0 1.605-.015 2.895-.015 3.3 0 .315.225.69.825.57A12.02 12.02 0 0 0 24 12c0-6.63-5.37-12-12-12z"/></svg>
<div style="text-align:left">
<div style="font-size:15px;font-weight:700">View Full Report &amp; Financial Model</div>
<div style="font-size:12px;color:var(--text-dim);margin-top:2px">Pitch memo (PDF) · 3-statement model (Excel) · Source files</div>
</div>
<span style="font-size:20px;color:var(--text-muted);margin-left:8px">→</span>
</a>
</section>

<div class="section-divider"></div>
<footer class="reveal"><p>Confidential Investment Memo · Data as of February 6, 2026 · Sources: Company filings (10-Q Q3'25, 10-K FY24, Q4'25 Earnings Release), CFRA Equity Research (Jan 31, 2026), IQVIA, S&P Global · For educational purposes only; not investment advice.</p></footer>

<script>
const progressBar=document.getElementById('scrollProgress');
window.addEventListener('scroll',()=>{const w=document.documentElement.scrollTop,h=document.documentElement.scrollHeight-document.documentElement.clientHeight;progressBar.style.width=(w/h*100)+'%'},{passive:true});

// === CURSOR GLOW + SHORT TRAIL ===
const cvs=document.getElementById('cursor-canvas'),ctx=cvs.getContext('2d');
let W,H,mX=-200,mY=-200;
function resize(){W=cvs.width=window.innerWidth;H=cvs.height=window.innerHeight}
resize();window.addEventListener('resize',resize);
document.addEventListener('mousemove',e=>{mX=e.clientX;mY=e.clientY});
document.addEventListener('mouseleave',()=>{mX=-200;mY=-200});

const trail=[];for(let i=0;i<12;i++)trail.push({x:-200,y:-200});

(function animate(){
  ctx.clearRect(0,0,W,H);

  // Update trail positions with easing
  trail[0].x+=(mX-trail[0].x)*0.25;
  trail[0].y+=(mY-trail[0].y)*0.25;
  for(let i=1;i<trail.length;i++){
    trail[i].x+=(trail[i-1].x-trail[i].x)*(0.22-i*0.012);
    trail[i].y+=(trail[i-1].y-trail[i].y)*(0.22-i*0.012);
  }

  if(mX>0){
    // Ambient glow
    const grd=ctx.createRadialGradient(trail[0].x,trail[0].y,0,trail[0].x,trail[0].y,180);
    grd.addColorStop(0,'rgba(230,57,70,0.07)');
    grd.addColorStop(0.5,'rgba(230,57,70,0.025)');
    grd.addColorStop(1,'transparent');
    ctx.beginPath();ctx.arc(trail[0].x,trail[0].y,180,0,Math.PI*2);ctx.fillStyle=grd;ctx.fill();

    // Smooth trail line
    ctx.beginPath();ctx.moveTo(trail[0].x,trail[0].y);
    for(let i=1;i<trail.length-1;i++){
      const xc=(trail[i].x+trail[i+1].x)/2;
      const yc=(trail[i].y+trail[i+1].y)/2;
      ctx.quadraticCurveTo(trail[i].x,trail[i].y,xc,yc);
    }
    ctx.strokeStyle='rgba(230,57,70,0.12)';ctx.lineWidth=2;ctx.lineCap='round';ctx.stroke();

    // Small bright dot
    ctx.beginPath();ctx.arc(trail[0].x,trail[0].y,3,0,Math.PI*2);
    ctx.fillStyle='rgba(230,57,70,0.45)';ctx.fill();
  }

  requestAnimationFrame(animate);
})();

const nav=document.getElementById('mainNav');
window.addEventListener('scroll',()=>{nav.classList.toggle('scrolled',window.scrollY>80)},{passive:true});

const sections=document.querySelectorAll('.section[id]'),navLinks=document.querySelectorAll('#navLinks a');
const sO=new IntersectionObserver(e=>{e.forEach(en=>{if(en.isIntersecting){navLinks.forEach(a=>a.classList.remove('active'));const al=document.querySelector(`#navLinks a[data-section="${en.target.id}"]`);if(al)al.classList.add('active')}})},{threshold:.3,rootMargin:'-80px 0px -40% 0px'});
sections.forEach(s=>sO.observe(s));

const rO=new IntersectionObserver(e=>{e.forEach(en=>{if(en.isIntersecting)en.target.classList.add('visible')})},{threshold:.08,rootMargin:'0px 0px -60px 0px'});
document.querySelectorAll('.reveal,.reveal-left,.reveal-scale,.section-header,.section-divider,.thesis-box').forEach(el=>rO.observe(el));

const bO=new IntersectionObserver(e=>{e.forEach(en=>{if(en.isIntersecting){en.target.querySelectorAll('[data-width]').forEach((b,i)=>{setTimeout(()=>{b.style.width=b.dataset.width},i*150)});bO.unobserve(en.target)}})},{threshold:.3});
document.querySelectorAll('#revenueMix,#marketShare').forEach(el=>bO.observe(el));

const tO=new IntersectionObserver(e=>{e.forEach(en=>{if(en.isIntersecting)en.target.classList.add('line-animated')})},{threshold:.15});
const tl=document.getElementById('catalystTimeline');if(tl)tO.observe(tl);

const cO=new IntersectionObserver(e=>{e.forEach(en=>{if(en.isIntersecting){const el=en.target,t=parseInt(el.dataset.count),p=el.dataset.prefix||'',d=2000,s=performance.now();
function u(n){const e=n-s,pr=Math.min(e/d,1),ea=1-Math.pow(1-pr,4),c=Math.round(ea*t);el.textContent=p+c.toLocaleString();if(pr<1)requestAnimationFrame(u)}
requestAnimationFrame(u);cO.unobserve(el)}})},{threshold:.5});
document.querySelectorAll('[data-count]').forEach(el=>cO.observe(el));

document.querySelectorAll('nav a[href^="#"]').forEach(a=>{a.addEventListener('click',e=>{e.preventDefault();const t=document.querySelector(a.getAttribute('href'));if(t){const top=t.getBoundingClientRect().top+window.pageYOffset-80;window.scrollTo({top,behavior:'smooth'})}})});

window.addEventListener('scroll',()=>{const y=window.scrollY;const orbs=document.querySelectorAll('.hero-orb');if(y<window.innerHeight*1.5){orbs[0].style.transform=`translate(${Math.sin(y*.002)*20}px,${y*.15}px)`;orbs[1].style.transform=`translate(${Math.cos(y*.003)*15}px,${y*-.1}px)`;orbs[2].style.transform=`translate(${Math.sin(y*.004)*10}px,${y*.08}px)`}},{passive:true});
</script>
</body>
</html>
